On August 28, the U.S. Department of Justice and the Drug Enforcement Administration announced that Walmart has agreed to pay $50 million to settle allegations that its pharmacies violated the Controlled Substances Act by dispensing invalid prescriptions for opioids and other controlled substances. The claims in the settlement are allegations only, with no admission of liability. A joint stipulation of dismissal has been filed in the U.S. District Court for the District of Delaware. In a regulatory filing, Walmart characterized the payment as "not material," noting its net income for the six months ended July 31 was approximately $11.79 billion.
Deputy Attorney General Stanley Woodward stated that the settlement demonstrates the Justice Department will enforce pharmacies' legal obligations regarding the dispensing of controlled substances, adding that "potential profit cannot justify fueling the opioid crisis." DEA Assistant Administrator Cheri Oz stated that dispensing unlawful prescriptions puts patients and communities at risk and undermines the system designed to prevent diversion and abuse. She noted the settlement addresses past conduct while also imposing forward-looking compliance obligations.
Turning to the background of the lawsuit, the government's complaint was filed on December 22, 2020, in the District of Delaware and amended in 2022, alleging that since June 26, 2013, Walmart dispensed large quantities of invalid prescriptions through both the knowing conduct of its compliance team and the knowing conduct of its pharmacists. The complaint alleged that the compliance team continued to fill prescriptions from certain prescribers it knew operated "pill mills." It also claimed that pharmacists submitted thousands of "refusal to fill" forms flagging suspicious prescriptions to corporate headquarters, but the compliance team failed to analyze these reports.
A DOJ press release quoted an email from a director on the compliance team: "Rather than analyzing refusal-to-fill reports, it would be better to use the marketing director's time to drive sales and patient awareness." Pharmacists were also alleged to have filled prescriptions they knew to be invalid, including those from known pill mill prescribers or those presenting clear red flags, such as dangerous opioid combinations, opioid and non-opioid "cocktails," excessive quantities of commonly abused opioids, over-prescribing patterns, and frequent early refills.
At the time of filing, the government sought statutory penalties of up to $67,627 per unlawful prescription and up to $15,691 for each suspicious order not reported to the DEA. Based on the scale of the allegations, theoretical fines could have reached billions of dollars, making the $50 million settlement a tiny fraction of that potential exposure. Walmart operates roughly 4,600 pharmacies nationwide, according to its website.
Beyond the payment, Walmart has entered into a memorandum of understanding with the DEA governing its future dispensing of controlled substances. Key terms include establishing a hotline for employees and patients to report suspected unlawful dispensing, proactive monitoring of dispensing patterns at its pharmacies to identify and address potential illegitimate dispensing, and creating a process to evaluate prescribers suspected of illegal prescribing. The public materials do not disclose the memorandum's duration, whether an independent monitor will be appointed, penalties for non-compliance, or a claims window for individual claimants.
In a statement, Walmart said it was pleased to resolve the matter and would continue to support pharmacists in their daily patient care duties. A DOJ spokesperson said the department will continue to pursue companies and individuals who fuel the opioid crisis through prescribing, marketing, dispensing, or distribution. The settlement text does not list the named prescribers, specify the exact number of prescriptions deemed invalid, or detail how the $50 million is allocated among fines, forfeiture, and state shares. Walmart has not admitted any wrongdoing. This settlement does not cover similar opioid cases involving manufacturers, wholesalers, or other pharmacy chains.